Clinical trials: Malignancies
Cancer
Post-chemotherapy Symptom Management SMART
Survivors of solid tumors (N=451) who completed curative intent chemotherapy for a solid tumor within the past 2 years were interviewed at baseline and stratified as high or low need for symptom management based on comorbidity…
- Trial name
- NCT03494166
- Testing
- Start with SMSH+TIPC, Start with SMSH alone
- Where
- 2 sites in United States
- Volunteers
- 498 people
- Sponsor
- University of Arizona
Rectal Cancer
Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer
This study will assess whether the Sienna+/Sentimag system, which involves a magnetic tracer, is effective in identifying the sentinel lymph node in rectal cancer and whether it is then feasible to remove this lymph node during…
- Trial name
- SentiRect (NCT02445456)
- Testing
- Sienna+ injection, MRI scan, Surgery to excise rectal cancer
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Oxford University Hospitals NHS Trust
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00867529
- Testing
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated…
- Trial name
- UpSwinG (NCT04179890)
- Testing
- Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®)
- Where
- United Kingdom
- Volunteers
- 462 people
- Sponsor
- Boehringer Ingelheim
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of copanlisib and how well it works when given together with eribulin in treating patients with triple negative breast cancer that has spread from where it first…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Trial name
- NCT04345913
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 43 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Neurofibroma, Neurofibromatosis Type 1
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
This pilot phase II trial studies how well selumetinib works in treating patients with neurofibromatosis type 1 and cutaneous neurofibromas.
- Conditions
- Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
- Trial name
- NCT02839720
- Testing
- Laboratory Biomarker Analysis, Selumetinib Sulfate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Liver Cancer
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors.
- Conditions
- Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT01171924
- Testing
- CUDC-101
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Curis, Inc.
Colorectal Cancer
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with…
- Trial name
- NCT05824559
- Testing
- ME-344, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- MEI Pharma, Inc.
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Melanoma
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
- Trial name
- NCT01449279
- Testing
- Ipilimumab, Radiation Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Liver Cancer, Hepatocellular Carcinoma
A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer. One treatment plan will be created using routine procedures and scans normally performed for radiation treatment…
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03338062
- Testing
- Hepatobiliary Iminodiacetic Acid (HIDA) scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Leukemia
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This study assesses the long-term safety and tolerability of dasatinib administered to patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia and experienced clinical benefit…
- Trial name
- START rollover (NCT00982488)
- Testing
- Dasatinib, Imatinib
- Where
- 72 sites in United States, Argentina and 22 more
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies how well edicotinib (JNJ-40346527) works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment.
- Trial name
- NCT03557970
- Testing
- Edicotinib, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Biliary Tract Cancer
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth…
- Trial name
- TreeTopp (NCT03093870)
- Testing
- Varlitinib, Capecitabine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 151 people
- Sponsor
- ASLAN Pharmaceuticals
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Prostate Cancer, Prostatic Neoplasms
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01020305
- Testing
- Temsirolimus, Casodex (bicalutamide)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sandy Srinivas
Multiple Myeloma in Relapse, Stage II Multiple Myeloma
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
This phase II trial is studying how well giving bevacizumab together with lenalidomide and dexamethasone works in treating patients with relapsed or refractory stage II or stage III multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00410605
- Testing
- bevacizumab, lenalidomide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01118351
- Testing
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.